CDMO enterprise focusing on small molecule innovative drugs「Laviana Pharma」 completed a round c financing of nearly 500 million yuan,Yingke PE led the investment.October Asset, HRVC Capital, Industrial Securities Capital, Yinglian Fund, Yueshi Capital, Sp@ce, Pingtan Yihe with follow the investment, the old shareholder Of HY Capital continue to chase investment. This round of financing is mainly used for the construction of Cangzhou Subsidiary CDMO base project, Hefei New drug R&D and GMP production base project and Shanghai Innovation accelerator laboratory.
Laviana Pharma Co., Ltd. founded in October 2005 ,headquartered in Jiangsu province.It provides contract development and manufacture service(CDMO) for the innovative pharmaceutical industry,The services cover all aspects of small molecule chemistry-process related field, from process development to contract manufacturing.The services which covers pre-clinical to post-marketing approval includes: process research, process optimization, pilot scale production and commercial-scale production,etc. In 2015, the company completed the restructuring, and has distributed research and development centers, production bases and overseas business centers in many places at home and abroad.
Customized R&D and production services for innovative pharmaceutical intermediates are customized R&D services and customized production services, which together constitute the integrated business of Laviana Pharma and its subsidiaries and are mainly applied in the field of pharmaceutical manufacturing. Among which, customized R&D refers to the process development, quality research and safety research of pharmaceutical intermediates for innovative drugs and other customized R&D services, mainly provided by Tianjin Laviana;Customized manufacturing refers to non-GMP pilot R&D and customized manufacturing services for pharmaceutical intermediates for innovative drugs, including non-GMP pilot R&D and manufacturing services for technology development stage to industrial production services for commercialization stage, mainly provided by Laviana Pharma. Both are high value-added services, which can reduce R&D and production costs of pharmaceutical enterprises, and help pharmaceutical enterprises effectively control R&D risks and improve R&D efficiency, optimize the supply chain, and bring new products to market at a faster speed.
According to the classification of life cycle, drugs can be divided into innovative drugs and generic drugs. Laviana Pharma mainly serves innovative drugs, especially the customized research, development and production services of new molecular entity drugs. At present, Laviana Pharma has more than one hundred annual service project orders, involving disease treatment fields covering tumor, central nervous system, metabolic system, etc., and has established long-term strategic partnership with many famous innovative drug customers around the world.
The pharmaceutical CMO/CDMO industry is a highly marketable and perfectly competitive industry. Worldwide, pharmaceutical CMO/CDMO enterprises mainly serve pharmaceutical companies and biotechnology companies in Europe, America, Japan and other developed regions. At present, the CMO/CDMO enterprises in the world are mainly concentrated in Europe, America and Asia, among which the CMO/CDMO enterprises in the Asian market are mainly concentrated in China and India.
With its competitive advantages in talent, infrastructure and cost structure, China has increasingly become the preferred strategic outsourcing destination for multinational pharmaceutical companies. China's pharmaceutical CDMO market has maintained a growth rate of more than 20% in recent years. In 2020, there will be more than 800 small molecule drugs under clinical development in China, indicating a huge market space.
With the advancement of the globalization of medical research and development,the horizontal development of multinational pharmaceutical enterprises,ie.,transform from pharmaceutical enterprise to treatment enterprise, further transform into health management enterprise for which the capacity and technical requirements of outsourcing enterprises will be higher and higher;With the advancement of precision medicine, the requirements for pharmaceutical development and manufacturing are becoming more and more stringent;As well as changes in the spectrum of human diseases, the division of labor of CDMO in the future will become more and more fine and standardized,all about these are good opportunities for Laviana Pharma undoubtedly,said, Chen Wenting, chairman and founder of Laviana Pharma.
About Yingke PE
Yingke PE capital ranks among the top 6 Chinese venture capital institutions, with an asset management scale of nearly 50 billion yuan, over 90% of which comes from large institutions. Yingke PE focuses on the distribution of core assets such as biomedicine and hard technology, and has invested in more than 300 leading enterprises. Yingke PE actively implements the dual strategy of biological medicine industry investment + life sciences industry holdings, to form the most comprehensive of biomedical research team,with nearly 150 innovative biomedical leading enterprises distributed in areas such as the biological vaccines, cancer diagnosis and treatment, rare disease, gene diagnosis and treatment, sets up the most extensive biological medicine industry covers the whole industry chain ecosystem, and Yingke PE is recognized by the market as "the best entrance of biomedical gold Track”.